Pakistan’s Fake Drug Crisis: DRAP’s Crackdown on Counterfeit Medicines

Counterfeit Medicines Threaten Pakistan’s Healthcare

Pakistan’s healthcare system is grappling with a dangerous fake drug crisis. According to the Ministry of National Health Services, 85% of medicines in Pakistan are either counterfeit or substandard, with DRAP reporting that half of the samples tested were fake. These include life-saving treatments for cancer, cardiovascular diseases, infections, and mental health conditions.

The consequences are devastating. Contaminated drugs often contain harmful additives or incorrect dosages, leading to severe side effects such as respiratory paralysis or even death. In 2012, a contaminated cardiology drug distributed in Lahore killed 125 people due to fatal bone-marrow suppression, highlighting the deadly impact of counterfeit medicines.

The crisis disproportionately affects the poor, who often rely on cheaper alternatives or free medicines from pharmacies. Rural areas, where drug regulation is weaker, are especially vulnerable. Patients unknowingly consume ineffective or dangerous drugs, worsening their health and burdening the healthcare system.

To combat this, DRAP has launched aggressive enforcement measures. Recent raids have shut down pharmacies and factories producing illegal medicines. In Nooriabad, a pharmaceutical factory was closed for manufacturing unregistered high-dose tramadol tablets, an opioid banned nationwide. In Lahore and Karachi, officials seized counterfeit batches of medicines falsely labeled under well-known brands, including treatments for allergies, infections, and infertility.

DRAP has also banned specific counterfeit batches, such as Duphalac syrup (batch 251986), Taskeen Dard tablets (batch 091), and Pain-Nil tablets (batch 01). These were removed from markets, and suppliers were tracked down for legal action.

Public awareness remains a critical challenge. Many citizens are unaware of how to identify fake drugs. Pharmacies like Dvago recommend checking for packaging irregularities, missing security seals, incorrect batch numbers, unusually low prices, and lack of proper labeling. Consumers are urged to buy only from licensed pharmacies, verify manufacturers, and report suspicious medicines.

While DRAP’s crackdown is a significant step forward, experts argue that stronger legislation, better-trained regulators, and improved enforcement are essential to fully address the crisis. Establishing pharmaceutical support programs for the poor and expanding drug surveillance could help protect vulnerable populations.

Pakistan’s fight against counterfeit medicines is far from over, but with consistent enforcement and public vigilance, the country can move toward safer healthcare and improved patient trust.